Aventis Pharmaceuticals Inc.

Rhone-poulenc Rorer Pharmaceuticals Inc.

Aventis Pharmaceuticals Products Inc.

Abbott Laboratories Corporation

Millennium Pharmaceuticals Limited

Aventis Pharma Deutschland, Gmbh

Ore Pharmaceuticals Inc.

Aventis Pharmaceuticals Product, Inc.

Martin P Maguire

Alfred P Spada

Michael R Myers

Paul E Persons

Wei He

Henry W Pauls

William R Ewing

Michael A Patane

Tricia J Vos

Yong Mi Choi-Sledeski

Mingshi Dai

Chin-Yi Jenny Hsu

Asher Zilberstein

Susan E Johnson

Andrew J Souers

Philip R Kym

Anil Vasudevan

Christopher F Claiborne

Matthew J LaMarche

Rajesh R Iyengar

Su-Jen Lai

Michael E Solomon

Mathew M Mulhern

Courtney A Cullis

Thomas H Marsilje, Iii

Christopher Blackburn

Dariusz Wodka

Ju Gao

John K Lynch

Jennifer C Freeman

Yong-Mi Choi

James A Brown

Mary Katherin Verzal

Matthew J Lamarche

Robert W Studt

Don D Cha

Jennifer L Che

James Brown

Mary Katherine Verzal

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor tyrosine kinase and/or Lck tyrosine kinase, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases

Provided are MC4-R binding compounds of the formula XVII: wherein Lis a linker group, and P, P, P, P, Z, Z, Z, Z, Z, t, s, and R are as described in the specification. Methods of using the compounds to treat MC4-R associated disorders, such as disorders associated with weight loss, are also provided.

Melanocortin-4 receptor binding compounds and methods of use thereof

This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula I:where m is zero or one, n is zero to two, Y is oxygen or &#x2014;N(R)&#x2014;, R, R, R, R, R, Rand Ring A are defined in the specification. Coumarin and quinolone compounds where Rand Rtogether form a fused benzo ring are preferred. The invention also provides compounds of formula VI where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.

Antagonists of melanin concentrating hormone receptor

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56 tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases

This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors. The method of treating cell proliferation and/or differentiation or mediator release using said quinazoline compounds and their use in pharmaceutical compositions is described.

Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase

Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties

Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties

This invention is directed to quinoline/quinoxaline compounds which inhibit platelet-derived growth factor or p56,tyrosine kinase activity, to pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cellular differentiation, proliferation, extracellular matrix production or mediator release and/or T cell activation and proliferation.

Quinoline and quinoxaline compounds which inhibit platelet-derived

Growing community of inventors

Woburn, MA, United States of America

Martin P Maguire